



# PharmaPendium®

## Release notes for November 2020

### Increased support for the assessment and mitigation of drug–drug interaction risks

As part of ongoing developments that support our users with the assessment and mitigation of drug–drug interaction (DDI) risks, we've greatly enhanced the content and search functionality of PharmaPendium's Metabolizing Enzyme and Transporters module.

We've normalized over 350 essential parameters and their values, including the AUC ratio,  $C_{\max}$  ratio,  $K_i$ ,  $K_m$ ,  $V_{\max}$  and  $IC_{50}$ , making it easier to compare data and make informed decisions about DDI risk.

To reduce post-processing time and increase search precision, we've enabled searching by value or value range, which enables much greater search precision. Value ranges can also be combined (e.g., a user could search for a substance with a  $K_i < 1 \mu M$  and an  $IC_{50} > 2 \mu M$ ). It is also possible to select preferred units for a search.

Potential use cases include the retrieval of data on drugs with particular inhibition profiles and information on approved drugs that interact with drugs similar to your candidate.

Export functionality has also been enhanced, with normalized parameters and units added to the range of data that users can share with in-house systems.

This is part of a continuous program to improve this unique database. This key release will help users:

- Optimize early drug candidate selection based on DDI risk
- Prioritize clinical DDI studies and even avoid unnecessary clinical DDI trials thanks to easy access to existing data
- Make informed risk mitigation studies

PharmaPendium is a trademark of Elsevier Limited.  
Copyright © 2021, Elsevier.

